

Rodger E Tiedemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8015822/publications.pdf>

Version: 2024-02-01

87
papers

3,755
citations

304743

22
h-index

128289

60
g-index

89
all docs

89
docs citations

89
times ranked

5751
citing authors

#	ARTICLE	IF	CITATIONS
1	Promiscuous Mutations Activate the Noncanonical NF- κ B Pathway in Multiple Myeloma. <i>Cancer Cell</i> , 2007, 12, 131-144.	16.8	941
2	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. <i>Cancer Cell</i> , 2008, 13, 167-180.	16.8	322
3	Genetic aberrations and survival in plasma cell leukemia. <i>Leukemia</i> , 2008, 22, 1044-1052.	7.2	299
4	Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma. <i>Cancer Cell</i> , 2013, 24, 289-304.	16.8	298
5	Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. <i>Blood</i> , 2007, 109, 5430-5438.	1.4	209
6	Once- versus twice-weekly bortezomib induction therapy with CyBORd in newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 115, 3416-3417.	1.4	179
7	BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. <i>Leukemia</i> , 2014, 28, 1657-1665.	7.2	171
8	Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. <i>Leukemia</i> , 2013, 27, 2357-2365.	7.2	142
9	Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome. <i>Cancer Research</i> , 2012, 72, 757-768.	0.9	113
10	RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. <i>Blood</i> , 2011, 117, 3847-3857.	1.4	97
11	Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. <i>Blood</i> , 2010, 115, 1594-1604.	1.4	95
12	Identification of a potent natural triterpenoid inhibitor of proteasome chymotrypsin-like activity and NF- κ B with antimyeloma activity in vitro and in vivo. <i>Blood</i> , 2009, 113, 4027-4037.	1.4	90
13	Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. <i>British Journal of Haematology</i> , 2013, 162, 483-488.	2.5	89
14	The Superantigen Streptococcal Pyrogenic Exotoxin C (SPE-C) Exhibits a Novel Mode of Action. <i>Journal of Experimental Medicine</i> , 1997, 186, 375-383.	8.5	76
15	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. <i>Blood</i> , 2007, 110, 4047-4054.	1.4	54
16	Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. <i>Journal of Clinical Investigation</i> , 2008, 118, 1750-64.	8.2	52
17	Cyproheptadine displays preclinical activity in myeloma and leukemia. <i>Blood</i> , 2008, 112, 760-769.	1.4	47
18	Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2015, 50, 204-208.	2.4	43

#	ARTICLE	IF	CITATIONS
19	Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. <i>Bone Marrow Transplantation</i> , 2015, 50, 95-99.	2.4	42
20	Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 563-565.	2.5	41
21	Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2668-2673.	1.3	27
22	The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2014, 124, 396-396.	1.4	27
23	Secondary primary malignancies during the lenalidomide+dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017, 6, 3-11.	2.8	24
24	Autologous stem cell transplant is an effective therapy for carefully selected patients with <sc>AL</sc> amyloidosis: experience of a single institution. <i>British Journal of Haematology</i> , 2014, 164, 722-728.	2.5	22
25	CyBorD induction therapy in clinical practice. <i>Bone Marrow Transplantation</i> , 2015, 50, 375-379.	2.4	21
26	Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. <i>Cancer Research</i> , 2019, 79, 5536-5549.	0.9	17
27	Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020, 55, 578-585.	2.4	17
28	Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 5401-5414.	7.0	16
29	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LRd) for untreated low-grade non-Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	4.1	15
30	Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival. <i>Leukemia and Lymphoma</i> , 2014, 55, 2284-2289.	1.3	13
31	Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 232-235.	1.3	12
32	Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11129-11147.	6.4	12
33	Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 555-560.	1.3	11
34	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394.	0.4	11
35	Getting to the root of the problem: the causes of relapse in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 251-254.	2.4	9
36	Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 285-292.	0.9	9

#	ARTICLE	IF	CITATIONS
37	<i>Listeria</i> Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. JAMA Oncology, 2020, 6, 293.	7.1	9
38	Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM). Blood, 2014, 124, 4773-4773.	1.4	8
39	Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults. British Journal of Haematology, 2015, 170, 384-390.	2.5	7
40	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 225-234.	0.4	7
41	sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution. Briefings in Bioinformatics, 2022, 23, .	6.5	6
42	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€”2. Mayo Clinic Proceedings, 2010, 85, 197-199.	3.0	5
43	Addition of Cyclophosphamide â€œOn Demandâ€”to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myelomaâ€”A Retrospective Review of a Single-center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e195-e203.	0.4	4
44	RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells,. Blood, 2011, 118, 3513-3513.	1.4	3
45	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis. Blood, 2013, 122, 3231-3231.	1.4	3
46	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. Blood, 2016, 128, 2137-2137.	1.4	3
47	Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy. Blood, 2016, 128, 5821-5821.	1.4	3
48	A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.. Blood, 2009, 114, 616-616.	1.4	2
49	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. Blood, 2019, 134, 62-62.	1.4	2
50	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. Blood, 2021, 138, 3055-3055.	1.4	2
51	An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment â€” validation of official dosing guidelines. Leukemia and Lymphoma, 2020, 61, 1860-1868.	1.3	1
52	Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e506-e509.	0.4	1
53	Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study. Blood, 2019, 134, 4570-4570.	1.4	1
54	PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.. Blood, 2007, 110, 671-671.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) â€“ Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (iMiDs),. Blood, 2011, 118, 3983-3983.	1.4	1
56	Follicular Lymphoma In Young Adults: Clinical Characteristics and Early Treatment Outcomes. Blood, 2013, 122, 4273-4273.	1.4	1
57	Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia. Blood, 2013, 122, 5398-5398.	1.4	1
58	A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma. Blood, 2014, 124, 4410-4410.	1.4	1
59	Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience. Blood, 2014, 124, 4756-4756.	1.4	1
60	Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevyliteâ„¢ Chain (HLC) Ratio Assessments. Blood, 2016, 128, 4632-4632.	1.4	1
61	Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival. Blood, 2012, 120, 595-595.	1.4	1
62	Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size. Blood, 2021, 138, 460-460.	1.4	1
63	Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma. Blood, 2021, 138, 1837-1837.	1.4	1
64	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. Leukemia and Lymphoma, 2019, 60, 2576-2579.	1.3	0
65	Syngeneic transplants for multiple myeloma â€“ a single center experience and review of the literature. Leukemia and Lymphoma, 2020, 61, 3519-3522.	1.3	0
66	A descriptive costâ€“analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating highâ€“dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. European Journal of Haematology, 2021, 107, 333-342.	2.2	0
67	Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 23-30.	3.0	0
68	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	1.4	0
69	Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.. Blood, 2006, 108, 367-367.	1.4	0
70	Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 (CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.. Blood, 2006, 108, 3421-3421.	1.4	0
71	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	1.4	0
72	Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.. Blood, 2009, 114, 601-601.	1.4	0

#	ARTICLE	IF	CITATIONS
73	RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.. Blood, 2009, 114, 602-602.	1.4	0
74	Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.. Blood, 2009, 114, 2801-2801.	1.4	0
75	Comparative Genomic Hybridization, Gene Expression Profiling and Whole Genome Sequencing Analysis of Disease Progression in Myeloma Reveals Vigorous Clonal Evolution in Patients with High Baseline Genetic Risk.. Blood, 2009, 114, 2810-2810.	1.4	0
76	Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial.. Blood, 2011, 118, 3982-3982.	1.4	0
77	Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre., Blood, 2011, 118, 4121-4121.	1.4	0
78	Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents. Blood, 2013, 122, 3396-3396.	1.4	0
79	Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years. Blood, 2013, 122, 5315-5315.	1.4	0
80	Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012. Blood, 2014, 124, 4447-4447.	1.4	0
81	Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience. Blood, 2015, 126, 1842-1842.	1.4	0
82	Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTM α , chain (HLC) Normalization. Blood, 2015, 126, 1982-1982.	1.4	0
83	Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience. Blood, 2015, 126, 5361-5361.	1.4	0
84	Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant. Blood, 2016, 128, 3457-3457.	1.4	0
85	Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab Na \bar{A} Ve Patients?. Blood, 2016, 128, 1795-1795.	1.4	0
86	Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience. Blood, 2018, 132, 4614-4614.	1.4	0
87	Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. Blood, 2019, 134, 5704-5704.	1.4	0